1. Introduction {#sec0001}
===============

Several initiatives are currently gathering information on the relationship between multiple sclerosis (MS) and coronavirus disease 2019 (COVID-19); still, few data are currently available ([@bib0001], [@bib0002], [@bib0003]). In particular, the use of disease-modifying therapies (DMTs) could affect COVID-19 outcomes by modulating the immune response (i.e., disease specific antibody production, cytokine production), which, in turn, might favor viral replication and/or confer protection from COVID-19 induced inflammatory response ([@bib0004]). We hereby report on two MS patients treated with cladribine tablets, with heterogeneous demographics and clinical features, who developed mild or no symptoms from COVID-19 and produced anti-SARS-CoV-2 antibodies, notwithstanding lymphocyte levels below normal values.

2. Case report {#sec0002}
==============

A 29-year-old man was diagnosed with relapsing-remitting MS in May 2018; Expanded Disability Status Scale (EDSS) score was 1.5. Due to clinical and radiological activity, he was commenced on cladribine tablets in July 2018. He screened negative for tuberculosis, HIV, hepatitis B and C, cytomegalovirus and varicella-zoster virus. Redosing of cladribine was performed in July 2019. Clinical, radiological and laboratory follow-ups were substantially uneventful. Blood tests before COVID-19 pandemic (January 2020) showed grade 3 lymphopenia (390 lymphocytes/µL), with reduced levels of CD4+ lymphocytes (66/µL), CD8+ lymphocytes (39/µL) and CD20+ lymphocytes (39/µL). In March 2020, while he was in Switzerland, he presented with anosmia, dysgeusia, diarrhea and fever, for which he was quarantined at home without testing. He fully recovered in few days using paracetamol as needed. In June 2020, he tested positive for anti-SARS-CoV-2 IgG antibodies on both qualitative lateral flow immunoassay (LFIA) and quantitative chemiluminescent immunoassay (CLIA).

A 61-year-old woman with concomitant hypertension and dyslipidemia, was diagnosed with relapsing-remitting MS in July 1994; EDSS was 2.5. She was initially treated with interferon beta1a, and, then, due to disease activity, switched to fingolimod in January 2017, and to cladribine in December 2019 (first year dosing was completed in January 2020). Blood tests before COVID-19 pandemic (February 2020) showed grade 1 lymphopenia (860 lymphocytes/µL). In May 2020, she tested positive for SARS-CoV-2 RNA on nasopharyngeal and oropharyngeal swabs, within tracing procedures of COVID-19 positive subjects. She did not present with any symptoms and tested negative on two following swabs in June 2020. In July 2020, she tested positive for anti-SARS-CoV-2 IgG antibodies on both LFIA and CLIA.

3. Discussion {#sec0003}
=============

Reduction of peripheral lymphocytes is expected during cladribine treatment. However, cladribine is a relatively poor T-cell depleting agent, and holds low risk of viral infections ([@bib0005]). Accordingly, in the phase 3 CLARITY study viral infections were uncommon and mild or moderate in severity ([@bib0006]). It is currently unknown whether lymphopenia represents a risk factor for morbidity and mortality from COVID-19, or is actually beneficial by preventing the abnormal systemic immune response ([@bib0002], [@bib0007]). We have shown that MS patients with lymphopenia following cladribine treatment can develop mild or no symptoms from COVID-19, suggesting that lymphopenia is not necessarily a risk factor for worse disease outcomes, and immunosuppressive DMTs do not necessarily need to be suspended or delayed in the course of the current pandemic ([@bib0008], [@bib0009]). This consideration applies to both a young, newly-diagnosed, drug-naïve patient and to an adult patient with comorbidities and long standing history of MS clinical features and treatments. Another relevant point is that patients treated with immunosuppressive DMTs, when infected, can present with mild or no COVID-19 symptoms and, being underdiagnosed, they might become an important source for viral spreading ([@bib0007]). As such, MS centers should carefully put into effect screening procedures (COVID-19 testing) while promoting social distancing and the use of individual protection devices for all consultations (e.g., face masks).

Our cases also suggest that MS patients with lymphopenia following cladribine treatment can develop anti-SARS-CoV-2 antibodies. This result was confirmed by two different serological tests to increase sensitivity and specificity ([@bib0010] 2020), and has definite implications for the possibility to respond to COVID-19 vaccination, once available, in this vulnerable population.

We acknowledge that the generalizability of our considerations is limited, deriving from the observation of two isolated cases, but we believe that they represent valuable hints needing confirmation in larger populations. Also, while COVID-19 testing for all MS patients dosing/redosing immunosuppressive DMTs has been suggested ([@bib0009]), there are differences between healthcare systems and local protocols that should be accounted for when translating our considerations in clinical practice.

In conclusion, our two patients with cladribine-induced lymphopenia, presented with mild or no COVID-19 symptoms, quickly recovered, and were able to develop anti-SARS-CoV-2 antibodies. While there is no evidence for the effects of cladribine and other DMTs on COVID-19, our cases suggest that benign clinical course and antibody production also occur in MS patients with lymphopenia.
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